IMPROVE-IT研究幻灯.pdfVIP

IMProved Reduction of Outcomes: Vytorin Efficacy International Trial A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome Trial Leadership Study Chairmen: Eugene Braunwald and Robert Califf TIMI Study Group: Christopher Cannon Robert Giugliano Amy McCagg Christina Pelland Sabina Murphy Erin Bohula May DCRI: Michael Blazing Craig Reist Jennifer White Yuliya Lokhnygina Curtis Campbell Cathy Martz Merck: Thomas Musliner Andrew Tershakovec Ann Kilian Rona Harmelin-Kadouri Paul DeLucca Steve Bird DSMB Chair: Scott Grundy CEC Chair: Stephen Wiviott National Lead Investigators and Steering Committee (1158 sites, 39 Countries) Enrique Gurfinkel¹ Jindrich Spinar Basil Lewis Tibor Duris Argentina (331) Czech Rep (371) Israel (589) Slovakia (121) Philip Aylward Peer Grande² Gaetano DeFerrari Anthony Dalby Andrew Tonkin* Denmark (576) Italy (593) S. Africa (186) Australia (116) Juri Voitk Ton Oude Ophuis Jose Lopez-Sendon Gerald Maurer Estonia (10) J. Wouter Jukema* Spain (551) Germany (935) Netherlands (1191) Antero Kesaniemi Mikael Dellborg Frans Van de Werf Finland (341) Harvey White